Respiratory Committee

Chair: Tom Stinchcombe, M.D.
Vice-Chairs: Dennis Wigle (Surgery)
Steven Schild (Radiation Oncology)
Stephen Graziano (Correlative Science)

1. Committee overview, and protocol accrual – Chair and Xiaofei Wang (slides only available)

2. Intergroup trials

   1. SWOG/NRG S1914: trial of immunotherapy followed by SBRT followed by immunotherapy Apar Ganti

   2. SWOG/Alliance S1827: PCI vs observation in ES-SCLC Jyoti Patel

   3. E5142 Erin Bertino

   4. NRG: SRS vs HA-WBRT SCLC brain metastases Steve Schild

   5. ALK biomarker trial- Luda Bazhenova

2. NCI Lung-MAP Jyoti Patel

Proposal: S1900X: A Phase II study of CB-839 and docetaxel in previously treated stage IV or recurrent squamous cell lung cancer patients harboring KEAP1 or NFE2L2 (NRF2) mutations Muhammad Furqan


4. Stage IV Non-Small Cell Lung Cancer

   1. A221504 - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta,
   Lyudmila Bazhenova
2. **AFT-42**: Nivolumab for patients with compromised organ function – Becca Heist, Phil Stella

3. **A082002**: A Randomized Phase III Trial of Nivolumab plus Ipilimumab with or without SBRT for PD-L1-Negative Stage IV Non-Small Cell Lung Cancer Steven E. Schild and Christine Bestvina

6. **Stage III Non-Small Cell Lung Cancer**

1. **AFT-16**: Induction PDL-1 inhibition – Helen Ross, Jim Urbanic

2. **AFT-46**: Chemo-immunotherapy for operable stage III NSCLC Linda Martin, Jyoti Patel

7. **Early Stage Non-Small Cell Lung Cancer and Surgical Studies - Dennis Wigle**

1. **A151216- ALCHEMIST**: Personalized Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer: Geoff Oxnard

2. **A081105**: Erlotinib vs observation

3. **A081801**: Adjuvant chemotherapy alone or in combination with pembrolizumab- Jacob Sands

4. **A082001**: Colchicine to Prevent Recurrences Of Treated Early Cancers of the Thorax (C-PROTECT)

8. **Small Cell Lung Cancer**

1. **NRG 005**: ChemoRT +/- atezolizumab- Helen Ross

2. **AFT-52**: ES-SCLC A phase II study first line platinum-based therapy and durvalumab followed by maintenance durvalumab +/- olaparib +/- cediranib for extensive stage small cell lung cancer- Jacob Sands

9. **Metastatic disease** AFT-51 metastasectomy trial Linda Martin